Sichenzia Ross Friedman Ference LLP Represents Rodman & Renshaw as Exclusive Placement Agent for a $3.77 Registered Direct Offering
Press Release – New York, NY – July 11, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Rodman & Renshaw, a unit of H.C. Wainwright& Co., LLC, as the exclusive placement agent for a registered direct offering of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye (“EyeGate”).
EyeGate sold an aggregate of 441,000 shares of common stock at a price of $2.25 per share and 2,776.5 shares of Series A Convertible Preferred Stock at a price of $1,000 per share. Additionally, investors in the offering received, for each share of common stock or for each share of common stock issuable upon conversion of a share of Series A Preferred Stock purchased in the registered direct offering, a warrant to purchase one-half of a share of common stock at an exercise price of $3.50 per share.
The shares of common stock and Series A Convertible Preferred Stock (including the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock) described above (but not the warrants or the shares of common stock underlying the warrants) were offered and sold by EyeGate pursuant to an effective shelf registration statement on Form S-3.
The Sichenzia Ross Friedman Ference LLP team was led by partners Greg Sichenzia, Jeff Fessler and Stephen Cohen.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Represents MoneyOnMobile, Inc., in a $5 Million Private Placement - February 12, 2018
- Sichenzia Ross Ference Kesner LLP Represents MoneyOnMobile, Inc., in $7.6 Million of Private Placements - February 8, 2018
- Sichenzia Ross Ference Kesner LLP Represents Roth Capital Partners and Brookline Securities in a $5.5 Million Public Offering of QBIO Med. - February 1, 2018